Drug Trial Radar · NCT00129259
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: May 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Sep 2005
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Sponsor type
- NIH
- Collaborators
- Immune Tolerance Network (ITN)
- First posted
- Aug 11, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 \[Ala-Ala\],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection. The purpose of this study is determine whether anti-CD3 mAb treatment can halt the progression of newly diagnosed type 1 diabetes.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAbBiological
Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
Diabetes Standard of Care TreatmentOther
Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
Iron supplementationDietary supplement
Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT)Time frame: Baseline (Pre-treatment), Month 24
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Diabetes Center at UCSF
San Francisco, California
Barbara Davis Center for Childhood Diabetes
Denver, Colorado
Yale University
New Haven, Connecticut
Medical College of Georgia
Augusta, Georgia
Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University
New York, New York
Benaroya Research Institute
Seattle, Washington
Pacific Northwest Research Institute/University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.